BIOCON LIMITED (BIOCON)
companyActive threads
Biocon Q2 net profit falls 57.3% to ₹56.7 crore
Biocon Ltd on Wednesday reported a 57.3 per cent decline in consolidated net profit to ₹56.7 crore in the September quarter of FY27. The company had posted a consolidated net profit of ₹132.8 crore in the corresponding period of the preceding fiscal year, Biocon Ltd said in a regulatory filing. Total income during the quarter rose to ₹4,423.4 crore, compared to ₹4,388.5 crore in the year-ago period, it added.
Biocon shares jump 3% as Pertuzumab biosimilar wins EMA backing
Biocon's Pertuzumab biosimilar has received a positive recommendation from the European Medicines Agency, moving it closer to EU marketing approval. The stock rose 3% on the news as investors anticipate a new revenue stream from the oncology drug. The final European Commission decision is expected in the coming months.
Biocon Jumps 3% on Rs 630-Crore Block Deal, Brazil Deal
Biocon shares rose nearly 3% on September 9 after a block deal worth Rs 630-638 crore saw shares change hands, with Active Pine likely the seller. The stock also gained on news of a Pertuzumab deal in Brazil, and trading volumes soared on the counter. The company remains in focus as investors digest the block deal and the strategic expansion in Latin America.
Biocon targets mid-20% margins as biosimilars grow
3 Min Read (Photo Credit : AI generated ) Biocon expects double-digit revenue growth in its biosimilars business to continue, with margins targeted at the mid-20% range and expected to improve further, the biopharmaceutical company told CNBC-TV18. Management said its target of reaching $1 billion in biosimilars revenue was a matter of when, rather than if, as the company expands its portfolio across markets.
Biocon wins 10-year Brazil Pertuzumab deal, shares rise 2%
Biocon has secured a 10-year supply contract with a Brazilian partner for its breast cancer biosimilar Pertuzumab, driving a 2% share gain. The company's CEO also signaled that biosimilars could soon reach $1 billion in revenue, citing strong insulin demand. This deal marks a strategic expansion in Latin America and reinforces Biocon's growing biosimilar portfolio.
Intelligence feed· 2 articles in 1440m
Biocon share price rises nearly 6% despite 52% dip in Q2 profit
Story first reported.
Biocon shares upgraded by Kotak Institutional Equities after recent correction improves risk-reward - CNBC TV18
Story first reported.